BridgeMD
New treatment option for Platinum-resistant Ovarian Cancer
Official title A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
ClinicalTrials.gov ID: NCT06515613
What this study is testing
What is CTIM-76?
CTIM-76 is an investigational medicine, given as an once-weekly, being studied as a potential treatment for platinum-resistant ovarian cancer.
Also referred to as CTIM-76 Claudin 6 bispecific Antibody.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants with CLDN6 positive platinum resistant/refractory ovarian, advanced testicular or advanced endometrial cancer.
- Participants with measurable disease per RECIST 1.1.
- ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks.
- Participants with adequate organ function.
You likely can't join if
- Evidence of central nervous system metastases, leptomeningeal disease or spinal cord compression.
- Uncontrolled significant active infection or any medical or other condition that in opinion of the Investigator would preclude the participant's...
- Concurrent participation in another investigational clinical trial.
The study team makes the final eligibility decision.
Where it's taking place
- Little Rock, Arkansas, United States
- Beverly Hills, California, United States
- Denver, Colorado, United States
- Boston, Massachusetts, United States
- Hackensack, New Jersey, United States
- New York, New York, United States
- Durham, North Carolina, United States
- Canton, Ohio, United States
- Portland, Oregon, United States
- Philadelphia, Pennsylvania, United States
- Providence, Rhode Island, United States
- Nashville, Tennessee, United States
- Dallas, Texas, United States
- London, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Little Rock, Arkansas, United States; Beverly Hills, California, United States; Denver, Colorado, United States; Boston, Massachusetts, United States; Hackensack, New Jersey, United States; New York, New York, United States and 8 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.